Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy

Avelumab (Bavencio, Merck Serono) is indicated 'as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial cancer who are progression-free following platinum-based chemotherapy'.

The dosage schedule is available in the summary of product characteristics for avelumab.

The list price is £768.00 per 200 mg/10 ml concentrate for solution for infusion vials (excluding VAT; BNF online, accessed February 2022).

The company has a commercial arrangement. This makes avelumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.